bioresorbable scaffold

^[1]

Contraindications

* no benefit, potential risk^[1]

↑ ^1.0 ^1.1 ^1.2 Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): A 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet 2016 Oct 28; PMID: https://www.ncbi.nlm.nih.gov/pubmed/2780689
Byrne RA, Kastrati A. Disappearing scaffolds, dissolving expectations. Lancet 2016 Oct 30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27806898